Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Cerilliant
Federal Trade Commission
Boehringer Ingelheim
Medtronic
Teva
Covington
Moodys
Colorcon

Generated: December 12, 2018

DrugPatentWatch Database Preview

IOPAMIDOL-250 Drug Profile

« Back to Dashboard

When do Iopamidol-250 patents expire, and when can generic versions of Iopamidol-250 launch?

Iopamidol-250 is a drug marketed by Cook Imaging, Fresenius Kabi Usa, and Hospira. and is included in five NDAs.

The generic ingredient in IOPAMIDOL-250 is iopamidol. There are eleven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the iopamidol profile page.

Summary for IOPAMIDOL-250
Drug patent expirations by year for IOPAMIDOL-250
Medical Subject Heading (MeSH) Categories for IOPAMIDOL-250
Synonyms for IOPAMIDOL-250
(S)-N,N'-bis(2-Hydroxy-1-(hydroxymethyl)ethyl)-2,4,6-triiodo-5-lactamidoisophthalamide
(S)-N,N'-Bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodoisophthaldiamide
(S)-N,N'-Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-2,4,6-triiodo-5-lactamidoisophthalamide
(S)-N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[(2-hydroxy-1-oxopropyl)amino]-2,4,6-triiodo-1,3-benzenedicarboxamide
1-N,3-N-bis(1,3-dihydroxypropan-2-yl)-5-[[(2S)-2-hydroxypropanoyl]amino]-2,4,6-triiodobenzene-1,3-dicarboxamide
1,3-Benzenedicarboxamide, N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-(((2S)-2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-
1,3-Benzenedicarboxamide, N,N'-bis(2-hydroxy-1-(hydroxymethyl)ethyl)-5-((2-hydroxy-1-oxopropyl)amino)-2,4,6-triiodo-, (S)-
166I930
60166-93-0
62883-00-5
AB00513941
AB00513941_02
AC1L23CM
AC1Q4PBP
ACT03261
AKOS015891034
AN-39478
API0003016
B 15000
B-15000
BPBio1_001037
BRD-K75868704-001-01-2
BRN 6250226
BSPBio_000941
C-23510
CAS-60166-93-0
CC-29575
CCG-213024
CHEBI:31711
CHEMBL1200932
CS-2917
D01797
D0O2HQ
DB08947
DR003545
DSSTox_CID_3158
DSSTox_GSID_23158
DSSTox_RID_76896
DTXSID1023158
EINECS 262-093-6
FT-0627281
Gastromiro
GP4065
HMS1570P03
HMS2097P03
HSDB 8075
HY-B0684
I01-8407
iomapidol
iopamidol
Iopamidol (JP17/USP)
Iopamidol [USAN:INN:BAN:JAN]
Iopamidol [USAN:USP:INN:BAN:JAN]
Iopamidol 300
Iopamidol injection (JP17)
Iopamidol-200
Iopamidol-200 in plastic container
Iopamidol-250 in plastic container
Iopamidol-300
Iopamidol-300 in plastic container
Iopamidol-370
Iopamidol-370 in plastic container
Iopamidolum
Iopamidolum [INN-Latin]
Iopamiro
Iopamiro 370
Iopamiron
Iopamiron (TN)
Iopamiron 300
Iopamiron 370
Iopamyron
Isovue
Isovue (TN)
Isovue 370
Isovue-128
Isovue-200
Isovue-250
Isovue-300
Isovue-370
Isovue-M 200
Isovue-M 300
Jopamiro
Jopamiron 200
JR13W81H44
KS-1421
L-(+)-N,N'-Bis(2-hydroxy-1-hydroxymethylethyl)-2,4,6-triiodo-5-lactamide isophthalamide
L-5alpha-Hydroxypropionylamino-2,4,6-triiodoisophthalic acid di(1,3-dihydroxy-2-propylamide)
L-5alpha-Idrossipropionilamino-2,4,6-triiodoisoftal-di(1,3-diidrossi-2-propilamide)
LS-29730
MolPort-003-848-224
N,N inverted exclamation mark -Bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2S)-2-hydroxy-1-oxopropyl]amino]-2,4,6-triiodo-1,3-benzenedicarboxamide
N,N'-bis(1,3-dihydroxypropan-2-yl)-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide
N,N'-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-{[(2S)-2-hydroxypropanoyl]amino}-2,4,6-triiodobenzene-1,3-dicarboxamide
N1,N3-bis(1,3-dihydroxypropan-2-yl)-5-[(2S)-2-hydroxypropanamido]-2,4,6-triiodobenzene-1,3-dicarboxamide
N1,N3-bis[2-hydroxy-1-(hydroxymethyl)ethyl]-5-[[(2S)-2-hydroxypropanoyl]amino]-2,4,6-triiodo-benzene-1,3-dicarboxamide
NCGC00016892-01
NCGC00016892-02
NCGC00016892-04
Niopam
Niopam 300
NSC-759636
NSC759636
Oypalomin
Pharmakon1600-01502304
Prestwick0_000871
Prestwick1_000871
Prestwick2_000871
Prestwick3_000871
Q-201245
s4532
SC-43948
Scanlux-300
Scanlux-370
SCHEMBL27781
Solutrast
Solutrast 370
SPBio_002862
SQ 13,396
SQ 13396
SQ-13396
Tox21_110668
Tox21_110668_1
UNII-JR13W81H44
XQZXYNRDCRIARQ-LURJTMIESA-N
ZINC3830947

US Patents and Regulatory Information for IOPAMIDOL-250

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cook Imaging IOPAMIDOL-250 iopamidol INJECTABLE;INJECTION 074881-002 Jul 28, 2000 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hospira IOPAMIDOL-250 iopamidol INJECTABLE;INJECTION 075005-001 Feb 24, 1998 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Fresenius Kabi Usa IOPAMIDOL-250 iopamidol INJECTABLE;INJECTION 074679-001 Apr 2, 1997 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hospira IOPAMIDOL-250 iopamidol INJECTABLE;INJECTION 074898-002 Dec 30, 1997 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Hospira IOPAMIDOL-250 IN PLASTIC CONTAINER iopamidol INJECTABLE;INJECTION 074636-002 Dec 30, 1997 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Moodys
Medtronic
McKinsey
Chinese Patent Office
Daiichi Sankyo
US Department of Justice
Baxter
Boehringer Ingelheim
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.